Abstract
Background : N-methyl-D-Aspartate (NMDA) receptor plays a main role in eliptogenisis and its inhibition has therapeutic significance in development of anticonvulsants. Prioritized quinazolinone molecules were synthesized and then evaluated in vivo by AOT and then for anticonvulsant activity in NMDA induced convulsion model. Method: In silico Screening of prioritized molecule was done by biological activity predictions and partition coefficient predictions (Log P) using PASS server and mol inspiration software respectively. This gave biological activity (BA) score for anticonvulsant activity and predicted Log P values (p Log P). The standard Log P required for anticonvulsant activities being more than 2.00, therefore molecules were also prioritized based on this p Log P criteria. Docking was performed on Vlife MDS 4.3 software. Result: Quinazolinone molecules were prioritized based upon docking score, ADME and BA score, synthesized and pharmacologically screened for anticonvulsant activity. Conclusion: SMMB 1 , SMMB 2 , SMMB 3 showed the prominent anticonvulsant activity as compared with memantine used as standard for in vivo anticonvulsant activity. Key words: Anticovulsant, Mol inspiration, NMDA, PASS, Pre ADMET, Quinazolinone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
